An Observational Study of Pediatric Subjects With Globoid Cell Leukodystrophy (GLD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01093105

Recruitment Status : Withdrawn (Study halted prior to enrollment of first participant)

First Posted : March 25, 2010

Last Update Posted : February 21, 2014

Sponsor:

Collaborators:

PharmaNet

Nextrials, Inc.

Information provided by (Responsible Party):

Shire

Study Description

Brief Summary:

The objective of this study is to evaluate the natural history of disease progression in infants with globoid cell leukodystrophy (GLD).

Condition or disease
Leukodystrophy, Globoid Cell

Detailed Description:

This study is being conducted to gather prospective data on disease progression in infants diagnosed with GLD. This study will be performed using protocol-defined, standardized assessments including clinical, developmental, and neurologic measures. All study visits will be conducted in the subject's home. No travel to the study site is necessary.

Study Design


Study Type :	Observational
Actual Enrollment :	0 participants
Observational Model:	Cohort
Time Perspective:	Prospective
Official Title:	A Multicenter, Prospective, Longitudinal, Observational Study of Pediatric Subjects With Globoid Cell Leukodystrophy (Krabbe Disease)

Resource links provided by the National Library of Medicine

Genetics Home Reference related topics: Krabbe disease RNAse T2-deficient leukoencephalopathy Leukoencephalopathy with vanishing white matter Megalencephalic leukoencephalopathy with subcortical cysts

MedlinePlus related topics: Leukodystrophies

Genetic and Rare Diseases Information Center resources: Leukodystrophy Krabbe Disease Sphingolipidosis

U.S. FDA Resources

Groups and Cohorts

Outcome Measures

Primary Outcome Measures :

To measure the change from baseline in growth parameters (eg, weight gain, linear growth, head circumference). [ Time Frame: 1 year ]
To determine the onset date of inadequate oral nutrition, hydration, and/or ventilation as a biomarker for survival [ Time Frame: 1 year ]

Secondary Outcome Measures :

To assess the change from baseline in clinical parameters of GLD disease progression from a standardized infant neurological examination and infant distress scales. [ Time Frame: 1 year ]
To assess the change from baseline in clinical parameters described in Hagberg's clinical staging. [ Time Frame: 1 year ]
To measure the time to absolute survival [ Time Frame: 1 year ]
To assess the AE experience in this patient population [ Time Frame: 1 year ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	up to 21 Months (Child)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Subjects with a documented diagnosis of GLD and clinical signs and symptoms consistent with that diagnosis

Criteria

Inclusion Criteria:

Subjects must meet all of the following criteria to be considered eligible for this study:

The subject has a documented diagnosis of GLD as evidenced by GALC enzyme activity or a GALC genotype that is predictive of GLD.
The subject must have clinical signs and symptoms consistent with the diagnosis of infantile GLD including at least 2 of the following:
1. Chronic difficulty with feeding or unexplained irritability or "fisting" or other signs of abnormal increased tone
2. CT or MRI imaging, if performed during diagnostic evaluation prior to enrollment, consistent with GLD
3. Failure to meet at least 2 age-specific developmental milestones consistent with GLD
4. Loss of deep tendon reflexes or abnormal visual fixation or optic atrophy
The subject has documented onset of signs and symptoms consistent with GLD at <12 months of age and is <21 months of age at time of study entry.
The subject was born at a gestational age of 35-41 weeks.
The subject had a birth weight of ≥2 kg.
At study entry, the subject must be able to maintain oral nutrition and hydration without the use of supportive measures, defined as use of a feeding tube.
At study entry, the subject must be able to maintain ventilation without the use of invasive supportive measures, defined as use of a breathing tube.
The subject must be able, in the opinion of the Investigator, to accommodate the protocol requirements, including feasibility of study visits.
The subject's parent(s) or legal guardian must have voluntarily signed an Institutional Review Board/Independent Ethics Committee-approved informed consent form after all relevant aspects of the study have been explained and discussed with the subject's parent(s), or legal guardian.

Exclusion Criteria: Subjects who meet any of the following criteria are not eligible for this study:

The subject has neurologic, hearing or vision impairment, difficulty swallowing or feeding, respiratory complications, behavioral disturbances, or other medical conditions that are not due to GLD and are likely to confound the scientific integrity or interpretation of study assessments, as determined by the Investigator.
The subject has received treatment with any investigational drug or a device within the 30 days prior to study enrollment through study completion.
The subject has received a cord blood or bone marrow transplant or is planning to receive one during the study.
The subject's parent(s) or legal guardian is unable to understand the nature, scope, and possible consequences of the study, or does not agree to comply with the protocol defined schedule of assessments.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01093105

Sponsors and Collaborators

Shire

PharmaNet

Nextrials, Inc.

Investigators


Study Director:	Lawrence Charnas, MD, PhD	Shire Human Genetic Therapies, Inc.

More Information


Responsible Party:	Shire
ClinicalTrials.gov Identifier:	NCT01093105 History of Changes
Other Study ID Numbers:	HGT-GLD-056
First Posted:	March 25, 2010 Key Record Dates
Last Update Posted:	February 21, 2014
Last Verified:	February 2014

Keywords provided by Shire:


Leukodystrophy, Globoid Cell Classic Globoid Cell Leukodystrophy Early-Onset Globoid Cell Leukodystrophy Globoid Cell Leukodystrophy Infantile Globoid Cell Leukodystrophy Late-Onset Globoid Cell Leukodystrophy Leukodystrophy, Globoid Cell, Classic Leukodystrophy, Globoid Cell, Early-Onset Leukodystrophy, Globoid Cell, Infantile	Leukodystrophy, Globoid Cell, Late-Onset Krabbe Leukodystrophy Krabbe's Leukodystrophy Globoid Cell Leukoencephalopathy Psychosine galactosylsphingosine (psychosine) beta-galactosidase Psychosine-UDP galactosyltransferase Krabbe Disease Krabbe's Disease

Additional relevant MeSH terms:


Leukodystrophy, Globoid Cell Hereditary Central Nervous System Demyelinating Diseases Brain Diseases, Metabolic, Inborn Brain Diseases, Metabolic Brain Diseases Central Nervous System Diseases Nervous System Diseases Sphingolipidoses Lysosomal Storage Diseases, Nervous System	Leukoencephalopathies Demyelinating Diseases Metabolism, Inborn Errors Genetic Diseases, Inborn Lipidoses Lipid Metabolism, Inborn Errors Lysosomal Storage Diseases Metabolic Diseases Lipid Metabolism Disorders

To Top